Premium
Endurance exercise and doxorubicin‐induced skeletal muscle dysfunction
Author(s) -
Hydock David Scott,
Bredahl Eric,
Gibson Noah,
Quinn Colin,
Schneider Carole,
Hayward Reid
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.712.27
Subject(s) - soleus muscle , medicine , endurance training , skeletal muscle , treadmill , muscle fatigue , endocrinology , pharmacology , physical medicine and rehabilitation , electromyography
The purpose of this study was to examine the role that prior endurance training plays in combating the skeletal muscle dysfunction and fatigue associated with the anticancer drug doxorubicin (DOX). Ten‐week old, male Sprague‐Dawley rats were randomly assigned to a treadmill training group (progressive treadmill training protocol 5 d/week for 10 weeks) or a sedentary group (normal cage activity for 10 weeks). Following activity treatments, animals were further randomized to receive DOX (15 mg/kg) or saline as a control. Five days following injections, soleus and extensor digitorum longus (EDL) maximal twitch force and fatigue were analyzed ex vivo . DOX treatment resulted in significant reductions in maximal twitch force in the soleus and EDL, and prior treadmill training attenuated this reduction in the soleus only. Additionally, treadmill training attenuated the increased fatigue associated with DOX in the soleus but not in the EDL. Exercise training provided protection against DOX‐induced muscle dysfunction and fatigue in the slow, oxidative soleus muscle but not in the fast, glycolytic EDL. This suggests that treadmill training's protection against DOX myotoxicity may be specific to type I muscle.